Protect Pharma completes sale of two patents and patents-applications to Grunenthal

Download PDF Copy

Reviewed

Feb 9 2011

Protect Pharmaceutical Corporation (OTC Bulletin Board: PRTT) announced that it has completed the sale of two patents and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes innovative pain drugs that address the large and underserved pain market.

Ram Sesha, Protect's Chief Operating Officer, said, "We are very happy to see Protect's programs are innovative and promising enough to attract someone like Grunenthal, a leader in pain drug discovery and research."

Protect still retains the patents related to abuse deterrent and once daily gastro-retentive drug delivery platforms and the corresponding three other ongoing projects. In the near term, Protect intends to proceed with a comprehensive program to develop and commercialize once-daily drugs for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy. Protect also plans to develop and commercialize once-daily opioid combinations as well as abuse-deterrent opioid combinations for moderate to severe pain.

Source:

http://www.protectpharm.com/

Posted in: Medical Patent News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Sapio Sciences and Ultima Genomics partner to advance multi-omics research

Evidence review questions ketamine’s role in chronic pain treatment

Daily walking reduces the chances of chronic low back pain

Nudibranchs (sea slugs) emerge as a promising source of cancer drugs

Do GLP-1 drugs shrink your muscles? New study explains the risks and what to do

Diabetes drugs linked to higher risk of rare optic nerve damage

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Scaling organ‑chip technology for human‑relevant drug discovery

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.